---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-033135"
form_type: "8-K"
ticker: "BCAX"
cik: "0002023658"
company_name: "Bicara Therapeutics Inc."
filed_at: "2026-05-11T23:59:59+00:00"
generated_at: "2026-05-14T19:12:30.376095+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bicara Q1 net loss $56.2M; cash $539.8M; appoints new CMO and CCO; advances ficerafusp alfa

## Summary
- Net loss of $56.2M for Q1 2026 vs $36.8M YoY; R&D expenses $47.5M, G&A $12.7M.
- Cash and marketable securities $539.8M at March 31, 2026; raised ~$161.8M in public offering.
- Bill Schelman promoted to CMO; David Raben transitions to Senior Executive Advisor; Chris Sarchi appointed CCO.
- Plan to initiate randomized study of ficerafusp alfa + pembrolizumab with loading and Q3W maintenance in 1L R/M HPV-negative HNSCC in Q3 2026.
- FORTIFI-HN01 pivotal trial substantially enrolled by year-end; interim analysis mid-2027.

## SEC filing metadata
- accession: 0001628280-26-033135
- form_type: 8-K
- ticker: BCAX
- cik: 0002023658
- company_name: Bicara Therapeutics Inc.
- filed_at: 2026-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023658/000162828026033135/0001628280-26-033135-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023658/000162828026033135/bcax-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-033135
- JSON: https://secwatch.observer/filing/0001628280-26-033135.json
- Plain text: https://secwatch.observer/filing/0001628280-26-033135.txt

## Source-grounded claims
- claim_id: 60ab645046b356e1935e5f244f16344ec79f922c
  claim: Bicara Therapeutics Inc. reported the first quarter ended March 31, 2026 results: net income Net loss totaled $56.2 million for the first quarter of 2026.
  evidence_excerpt: Bicara Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/2023658/000162828026033135/0001628280-26-033135-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.